Pharmacoflash 21 : Miscellanous (1)

14:00 • 666 • Real-World Evaluation of Apixaban Dose-Reduction Criteria: Serum Creatinine Versus Creatinine Clearance > Y. Yuko Shimamoto 14:06 • 164 • Optimizing Elexacaftor/Tezacaftor/Ivacaftor Therapy: When Biological "Over-Response" Triggers Toxicity > A. Alexandre Destere 14:12 • 619 • Metabolic determinants of rivaroxaban pharmacokinetics: unveiling the inflammatory axis > C. Catherine Feliu 14:18 • 479 • Receptor Occupancy–Based Analysis Incorporating Developmental Changes in infants preterm During Caffeine Therapy > H. Haruka Ide 14:24 • 371 • Mycophenolic acid in systemic sclerosis-related interstitial lung disease patients: exposure and efficacy assessment > F. Florian LEMAITRE 14:30 • 625 • Clinical Relevance of CYP2C19 Genotyping for Therapeutic Strategy Optimization in Clopidogrel-Treated Patients > S. Sylvie Quaranta 14:36 • 684 • Physiologically-Based Pharmacokinetic and Pharmacodynamic Modeling to Optimize Rivaroxaban Dosing in CA-VTE Patients Coadministered with Ensartinib > X. Xiaoqin Liu